Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a transaction involving a $41.00 per share cash payment plus contingent value rights.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Shareholders receive $41.00 per share in cash plus one contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding common stock, restricted stock units (RSUs), and certain stock options were converted into the right to receive the merger consideration or were cancelled.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides a definitive cash exit and potential upside through CVRs.

Positives

• Shareholders receive a defined cash consideration of $41.00 per share.
• Potential for additional upside of up to $4.00 per share through contingent value rights (CVRs).
• Successful completion of the tender offer and merger process.

Negatives

• Stock options with an exercise price equal to or greater than $45.00 were cancelled without consideration.
• The company ceases to exist as an independent publicly traded entity.

Risks

• The $4.00 per share CVR payment is contingent upon the achievement of specific milestones, which may not be met.
• The CVRs are non-transferable, limiting liquidity for holders.

Future Outlook

The company has been acquired by Biogen and is now a wholly owned subsidiary; therefore, no independent future guidance is provided.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large-cap biopharmaceutical companies (Biogen) consolidating smaller, specialized biotech firms (Apellis) to bolster their pipelines, particularly in the ophthalmology or rare disease spaces.

Comparison to Industry Standards

• The use of CVRs is a standard mechanism in biotech M&A to bridge valuation gaps between buyers and sellers regarding clinical trial outcomes.
• The acquisition structure is consistent with recent industry precedents for mid-cap biotech buyouts.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and management are subject to the integration plans of the parent company, Biogen.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement for potential future payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Rights, Tender Offer